Struggling With Great Stock Picks? Discover StockInvest.us Top Gems!
NASDAQ:ONCE
Delisted

Spark Therapeutics Stock Price (Quote)

$113.57
+0 (+0%)
At Close: Jan 24, 2020

Range Low Price High Price Comment
30 days $113.57 $113.57 Friday, 24th Jan 2020 ONCE stock ended at $113.57. During the day the stock fluctuated 0% from a day low at $113.57 to a day high of $113.57.
90 days $108.00 $113.90
52 weeks $40.64 $114.20

Historical Spark Therapeutics prices

Date Open High Low Close Volume
Oct 07, 2019 $97.47 $98.99 $97.47 $98.02 252 017
Oct 04, 2019 $97.34 $97.83 $96.21 $97.56 533 269
Oct 03, 2019 $96.58 $97.57 $96.07 $97.12 413 050
Oct 02, 2019 $96.76 $97.65 $95.92 $96.65 759 519
Oct 01, 2019 $97.58 $98.19 $96.80 $96.85 396 869
Sep 30, 2019 $97.41 $98.15 $96.85 $96.98 365 284
Sep 27, 2019 $97.61 $98.42 $96.65 $97.41 567 174
Sep 26, 2019 $98.14 $98.65 $96.67 $96.98 811 812
Sep 25, 2019 $100.46 $101.02 $97.75 $98.02 1 504 505
Sep 24, 2019 $102.17 $102.60 $100.85 $101.65 438 541
Sep 23, 2019 $102.42 $103.53 $101.75 $101.95 310 749
Sep 20, 2019 $102.15 $103.00 $100.90 $102.36 644 060
Sep 19, 2019 $104.00 $104.00 $101.81 $102.01 794 637
Sep 18, 2019 $104.38 $104.82 $102.96 $104.11 583 407
Sep 17, 2019 $104.61 $105.65 $104.05 $104.40 291 721
Sep 16, 2019 $104.25 $104.99 $103.74 $104.80 283 364
Sep 13, 2019 $105.55 $105.75 $104.04 $104.77 403 746
Sep 12, 2019 $102.24 $105.96 $102.20 $105.65 877 184
Sep 11, 2019 $101.86 $102.22 $100.15 $102.06 413 293
Sep 10, 2019 $100.44 $101.75 $100.00 $101.74 389 763
Sep 09, 2019 $101.23 $101.93 $100.28 $100.57 222 341
Sep 06, 2019 $101.00 $102.21 $99.93 $101.07 683 417
Sep 05, 2019 $99.91 $101.56 $99.00 $100.86 1 071 747
Sep 04, 2019 $99.03 $99.53 $97.80 $99.30 416 739
Sep 03, 2019 $98.50 $99.44 $97.50 $98.67 602 289
Click to get the best stock tips daily for free!

About Spark Therapeutics

Spark Therapeutics Spark Therapeutics, Inc. focuses on the development of gene therapy products for patients suffering from debilitating genetic diseases. The company develops SPK-RPE65, which is in Phase III clinical trial for the treatment of genetic blinding conditions called inherited retinal diseases caused by non sex-linked, autosomal recessive, or mutations in the RPE65 gene; and SPK-CHM that is in Phase I/II clinical trial for the treatment of choroideremia... ONCE Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT